Curevac advances cancer vaccine candidate cvgbm to part b of phase 1 study in patients with resected glioblastoma

First patient administered in dose-confirmation part b of phase 1 study with mrna-based, multiepitope cancer vaccine candidate cvgbm part b expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of cvgbm tÜbingen, germany and boston, ma / accesswire / august 15, 2024 / curevac n.v. (nasdaq:cvac) ("curevac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mrna"), today announced the start of the dose-confirmation part b of its ongoing phase 1 study in patients with resected glioblastoma.
CVAC Ratings Summary
CVAC Quant Ranking